全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...
药学学报  2013 

羰基钌一氧化碳释放分子的毒理、组织分布及其与血液内源性物质的相互作用

, PP. 1677-1687

Keywords: 一氧化碳释放分子,毒理,组织分布,相互作用

Full-Text   Cite this paper   Add to My Lib

Abstract:

co是人体内类似于no的信使分子,过渡金属羰基配合物是co的固化形式。大量研究表明羰基钌一氧化碳释放分子(corms)具有很强的药理活性,本文合成了5个羰基钌corms,从毒理、组织分布及与血液内源性物质的相互作用等方面进行了研究。研究主要包含以下方面:①通过细胞生长抑制实验获得它们对成纤维细胞的ic50介于212.9~2089.2μmol·l-1;利用小鼠测得它们的经口ld50介于800~1600mg·kg-1;血液生化分析及透射电镜检查表明多次给药后corms1及corms5对wistar大鼠肝、肾功能无显著影响,但对肝肾组织细胞造成损伤。②小鼠腹腔给药后,以icp-aes检测corms组织分布,结果表明羰基钌corms在体内主要分布于血液、肝、肾,在心、脾、肺中分布较少,不能通过血脑屏障进入脑组织;corms结构中的非co配体对化合物的吸收分布有较大影响。③corms可使牛血清白蛋白的荧光增强,其强度与corms的加入量呈正比关系;corms与gsh的反应产物随条件不同而呈现二羰基钌或三羰基钌配合物两种形态。

References

[1]  marksgs,brienjf,nakatsuk,etal.doescarbonmonoxidehaveaphysiologicalfunction?[j].trendspharmacolsci,1991,12:185-188.
[2]  motterlinir,gonzalesa,forestir,etal.hemeoxygenase-1derivedcarbonmonoxidecontributestothesuppressionofacutehypertensiveresponsesinvivo[j].circres,1998,83:568-577.
[3]  otterbeinle.carbonmonoxide:innovativeanti-inflammatorypropertiesofanage-oldgasmolecule[j].antioxidredoxsignal,2002,4:309-319.
[4]  johnsontr,mannbe,clarkje,etal.metalcarbonyls:anewclassofpharmaceuticals?[j].angewcheminted,2003,42:3722-3729.
[5]  mannbe,motterlinir.coandnoinmedicine[j].chemcommun(camb),2007,(41):4197-4208.
[6]  lamonbd,zhangff,purin,etal.dualpathwaysofcarbonmonoxide-mediatedvasoregulationmodulationbyredoxmechanisms[j].circres,2009,105:775-783.
[7]  motterlinir,otterbeinle.thetherapeuticpotentialofcarbonmonoxide[j].natrevdrugdiscov,2010,9:728-743.
[8]  otterbeinle,bachfh,alamj,etal.carbonmonoxidehasanti-inflammatoryeffectsinvolvingthemitogen-activatedproteinkinasepathway[j].natmed,2000,6:422-428.
[9]  satok,ballaj,otterbeinle,etal.carbonmonoxidegeneratedbyhemeoxygenase-1suppressestherejectionofmouse-to-ratcardiactransplants[j].jimmunol,2001,166:4185-4194.
[10]  lavitranom,smolenskirt,musumecia,etal.carbonmonoxideimprovescardiacenergeticsandsafeguardstheheartduringreperfusionaftercardiopulmonarybypassinpigs[j].fasebj,2004,18:1093-1095.
[11]  hewisonl,crooksh,mannbe,etal.newtypesofco-releasingmolecules(co-rms),basedonirondithiocarbamatecomplexesand[fe(co)3i(s2coet)][j].organometallics,2012,31:5823-5834.
[12]  clarkje,naughtonp,shureys,etal.cardioprotectiveactionsbyawater-solublecarbonmonoxide-releasingmolecule[j].circres,2003,93:e2-e8.
[13]  santos-silvat,mukhopadhyaya,seixasjd,etal.corm-3reactivitytowardproteins:thecrystalstructureofaru(ⅱ)dicarbonyl-lysozymecomplex[j].jamchemsoc,2011,133:1192-1195.
[14]  forestir,hammadj,clarkje,etal.vasoactivepropertiesofcorm-3,anovelwater-solublecarbonmonoxide-releasingmolecule[j].brjpharmacol,2004,142:453-460.
[15]  desmardm,forestir,morind,etal.differentialantibacterialactivityagainstpseudomonasaeruginosabycarbonmonoxide-releasingmolecules[j].antioxidredoxsignal,2012,16:153-163.
[16]  mannbe.co-releasingmolecules:apersonalview[j].organometallics,2012,31:5728-5735.
[17]  romanskis,krausb,schatzschneideru,etal.acyloxybutadieneirontricarbonylcomplexesasenzyme-triggeredco-releasingmolecules(et-corms)[j].angewcheminted,2011,50:2392-2396.
[18]  kretschmerr,gessnerg,görlsh,etal.dicarbonyl-bis(cysteamine)iron(ⅱ):alightinducedcarbonmonoxidereleasingmoleculebasedoniron(corm-s1)[j].jinorgbiochem,2011,105:6-9.
[19]  johnsontr,mannbe,teasdaleip,etal.metalcarbonylsaspharmaceuticals?[ru(co)3cl(glycinate)],aco-releasingmoleculewithanextensiveaqueoussolutionchemistry[j].daltontrans,2007,15:1500-1508.
[20]  schledee,genschowe,spielmannh,etal.oralacutetoxicclassmethod:asuccessfulalternativetotheoralld50test[j].regultoxicolpharmacol,2005,42:15-23.
[21]  martinm,maciasm,escamesg,etal.melatonin-inducedincreasedactivityoftherespiratorychaincomplexesiandivcanpreventmitochondrialdamageinducedbyrutheniumredinvivo[j].jpinealres,2000,28:242-248.
[22]  clarkemj.rutheniummetallopharmaceuticals[j].coordchemrev,2003,236:209-233.
[23]  delaneys,pascalym,bhattacharyapk,etal.oxidativedamagebyrutheniumcomplexescontainingthedipyridophenazineligandoritsderivatives:afocusonintercalation[j].inorgchem,2002,41:1966-1974.
[24]  ciftcio,ozdemiri,cakiro,etal.thedeterminationofoxidativedamageinhearttissueofratscausedbyruthenium(ⅱ)andgold(i)n-heterocycliccarbenecomplexes[j].toxicolindhealth,2011,27:735-741.
[25]  seixasjd,mukhopadhyaya,santos-silvat,etal.characterizationofaversatileorganometallicpro-drug(corm)forexperimentalcobasedtherapeutics[j].daltontrans,2013,42:5985-5998.
[26]  trynda-lemieszl,kepplerbk,koz?lowskih.studiesontheinteractionsbetweenhumanserumalbuminandimidazolium[trans-tetrachlorobis(imidazol)ruthenate(ⅱi)][j].jinorgbiochem,1999,73:123-128.
[27]  beckfordfa.reactionoftheanticancerorganometallicrutheniumcompound,[(η6-p-cymene)ru(atsc)cl]pf6withhumanserumalbumin[j].intjinorgchem,2010:1-7.
[28]  wangfy,xujj,habtemariama,etal.competitionbetweenglutathioneandguanineforaruthenium(ⅱ)areneanticancercomplex:detectionofasulfenatointermediate[j].jamchemsoc,2005,127:17734-17743.
[29]  motterlinir,clarkje,forestir,etal.carbonmonoxide–releasingmoleculescharacterizationofbiochemicalandvascularactivities[j].circres,2002,90:e17-e24.
[30]  gonzalezma,frynl,burtr,etal.designedironcarbonylsascarbonmonoxide(co)releasingmolecules:rapidcoreleaseanddeliverytomyoglobininaqueousbuffer,andvasorelaxationofmouseaorta[j].inorgchem,2011,50:3127-3134.
[31]  marquesar,kromerl,gallodj,etal.generationofcarbonmonoxidereleasingmolecules(co-rms)asdrugcandidatesforthetreatmentofacuteliverinjury:targetingofco-rmstotheliver[j].organometallics,2012,31:5810-5822.
[32]  valensind,anzinip,gaggellie,etal.fac-{ru(co)3}2+selectivelytargetsthehistidineresiduesoftheβ-amyloidpeptide1-28.implicationsfornewalzheimer'sdiseasetreatmentsbasedonrutheniumcomplexes[j].inorgchem,2010,49:4720-4722.
[33]  wangfy,weidts,xujj,etal.identificationofclustersfromreactionsofrutheniumareneanticancercomplexwithglutathioneusingnanoscaleliquidchromatographyfouriertransformioncyclotronmassspectrometrycombinedwith18o-labeling[j].jamsocmassspectrom,2008,19:544-549.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133